Trial Profile
A Single Institution Study Evaluating Efficacy Of Abiraterone And Enzalutamide As Direct Sequential Treatments For Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Apr 2017
Price :
$35
*
At a glance
- Drugs Abiraterone (Primary) ; Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 06 Apr 2017 New trial record
- 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium.